MARKET

COGT

COGT

Cogent Biosciences Inc
NASDAQ
35.24
-3.25
-8.44%
After Hours: 35.24 0 0.00% 16:00 04/01 EDT
OPEN
37.78
PREV CLOSE
38.49
HIGH
38.00
LOW
34.35
VOLUME
8.57M
TURNOVER
--
52 WEEK HIGH
43.73
52 WEEK LOW
3.720
MARKET CAP
5.72B
P/E (TTM)
-16.3458
1D
5D
1M
3M
1Y
5Y
1D
Cogent submits FDA NDA for bezuclastinib in second-line GIST under RTOR program
Reuters · 7h ago
Fairmount Funds Management disposes of USD 243M Cogent Biosciences common shares
Reuters · 18h ago
Weekly Report: what happened at COGT last week (0323-0327)?
Weekly Report · 2d ago
Cogent Biosciences Advances CGT6297 Into First-in-Human Trial for PIK3CA-Driven Cancers
TipRanks · 5d ago
Assessing Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Rising Institutional Interest
Simply Wall St · 03/24 20:11
Weekly Report: what happened at COGT last week (0316-0320)?
Weekly Report · 03/23 09:29
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
The Motley Fool · 03/21 23:33
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
The Motley Fool · 03/21 22:43
More
About COGT
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.

Webull offers Cogent Biosciences Inc stock information, including NASDAQ: COGT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COGT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading COGT stock methods without spending real money on the virtual paper trading platform.